Decoding Antibody Discovery — The Future of Next-Gen Biologics Webinar
The webinar "Decoding Antibody Discovery — The Future of Next-Gen Biologics," held online on December 13, 2022, features experts Christian Olsen and Dr. Nimesh Joseph discussing current trends and innovative workflows in monoclonal antibody research and discovery to optimize early-stage biologics development, followed by a live Q&A session.
Antibodies have established themselves as one of the most important classes within the biologics space, and developing these therapeutics requires a series of successful decisions throughout the early-discovery process. Antibody discovery is a complex and often circuitous route, which, if not efficiently optimized, can cost investigators valuable time and money. In this webinar, subject matter experts Christian Olsen and Dr. Nimesh Joseph provide an overview of current trends in monoclonal antibody research and discovery, and discuss how science and technology are converging to create cutting-edge workflows designed to drive innovation and breakthroughs in the largest biologics therapeutic class today.
A live Q&A session follows the presentations, offering attendees a chance to pose questions to the expert panelists.
Featured Speakers
- Christian Olsen, VP Strategy, Protein Therapeutics, Luma
- Nimesh Joseph, Senior Solution Engineer, Dotmatics
Nimesh Joseph is a trained cell and molecular biologist with over 20 years of research experience, primarily engaged in target validation studies across both academia and biotech. In his current role at Dotmatics, Nimesh oversees solution design for leading pharmaceutical and biotech research teams.
Event Details
- Date: Dec 13, 2022
- Time: 8:00am PDT / 11:00am EST / 17:00 CET
- Location: Online
Related
Dotmatics at Antibody Engineering & Therapeutics 2024
Dotmatics will exhibit at the Antibody Engineering & Therapeutics Conference from December 15-18, 2024, at the Marriott Marquis San Diego Marina (booth 313), featuring a presentation by Christian Olsen on December 16 about how Geneious Luma enhances therapeutic antibody engineering through adaptive workflows and data aggregation.
Dotmatics Launches BioGlyph Luma to Accelerate the Future of Protein Design & Engineering
Dotmatics has launched BioGlyph Luma, a next-generation protein design and engineering solution integrated into its Luma Scientific Intelligence Platform, which addresses the Design phase of the protein therapeutics research cycle by enabling real-time traceability, scalable registration, and seamless integration with existing scientific tools to accelerate multimodal biologic R&D workflows with precision and data-driven automation.
Dotmatics at PEGS 2024
Dotmatics will be exhibiting at PEGS 2024, held May 13-17 at the Omni Hotel Boston, where the summit offers leading biologics innovation insights, including drug development, protein and antibody engineering, immunotherapy, AI applications, and networking opportunities.
Managing the Madness: Three Must-Dos for Tracking Multiformat Antibody R&D
The article discusses the increasing complexity of biologic antibody therapeutics, especially multiformat antibodies like bispecifics and antibody-drug conjugates, emphasizing the critical need for research teams to efficiently integrate diverse data types and collaborate across disciplines using unified software and dataflows to track and optimize these complex antibody designs.
A Universal Language for Multispecific Antibodies
The article discusses the challenges of naming structurally diverse multispecific antibodies (MsAbs) and advocates for a building-block-based nomenclature system that captures both component parts and assembly logic, thereby enhancing collaborative research, enabling precise differentiation of complex biologics, and generating structured, AI-ready data to support current workflows and future protein engineering innovations.
New Dotmatics solution to streamline your antibody discovery process
Dotmatics' new Luma Antibody & Protein Engineering solution, built on the AI-native Geneious Luma platform and integrated with tools like GraphPad Prism, streamlines the complex antibody discovery and development process by unifying data, teams, and experimental phases within a single, collaborative environment to enhance biologics R&D productivity and overcome challenges of siloed data and rigid workflows.